Madrigal Pharmaceuticals (MDGL)

• Market cap: $9.24B
• 1 day: -0.59%
• 5 days: 6.16%
• 1 month: 38.15%
• 3 months: 51.80%
• 6 months: 33.20%
• Year to date: 31.38%
• 1 year: 61.15%
• 5 years: 288.46%
• 10 years: 543.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

129% more call options, than puts

Call options by funds: $271M | Put options by funds: $118M

0% more funds holding in top 10

Funds holding in top 10: 12 [Q1] → 12 (+0) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 107

1.55% less ownership

Funds ownership: 106.97% [Q1] → 105.42% (-1.55%) [Q2]

6% less funds holding

Funds holding: 318 [Q1] → 299 (-19) [Q2]

9% less capital invested

Capital invested by funds: $7.82B [Q1] → $7.08B (-$732M) [Q2]

22% less first-time investments, than exits

New positions opened: 40 | Existing positions closed: 51

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $428 4% upside
• Avg. target: $498 21% upside
• High target: $554 34% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

TD Cowen Ritu Baral	34% upside $554	Buy Maintained	26 Aug 2025
JMP Securities Jonathan Wolleben	18% upside $485	Market Outperform Maintained	20 Aug 2025
UBS Eliana Merle	27% upside $523	Buy Maintained	12 Aug 2025
Canaccord Genuity Edward Nash	4% upside $428	Buy Maintained	6 Aug 2025